Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

作者：Rong Ding, Jin‐Feng Bai, Z. Jin, Yao Xiao, Jian‐Jian Chen, Xiao‐Li Zhu, Yu‐Jing Xin, Jin‐Zhang Chen, Jun Tie, Kang‐Shun Zhu, Lan Zhang, Hai‐Bin Shi, Rui‐Bao Liu, Aibing Xu, Fanpu Ji, Ming‐Sheng Huang, Jian‐Song Ji, Chun‐Wang Yuan, W. B. Yang, Guo‐Hui Xu, Qiang Tu, Hua Jiang, Hai‐Bo Shao, Bao‐Qi Shi, Meng-Lin Huang, Bin‐Yan Zhong, Hai‐Dong Zhu, Zhenggang Ren, G. Teng · 发表于：Alimentary Pharmacology & Therapeutics · 年份：2026 · DOI：10.1111/apt.70612 · 被引用次数：3 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies、Liver Disease Diagnosis and Treatment

BACKGROUND: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. METHODS: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T-C-A) or camrelizumab and apatinib alone (C-A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety. RESULTS: A total of 252 HCC patients were included (T-C-A group, n = 183; C-A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group (24.2 months [95% CI: 21.4-33.4] vs. 15.2 months [95% CI: 9.8-21.0]; p < 0.001). The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group (p < 0.001). Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and...